Population-based scReening Over SPEech for Clinical Trials in Alzheimer’s Disease

Population-based scReening Over SPEech for Clinical Trials in Alzheimer’s Disease - Prospect-AD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027352

Enrollment

300

Registered

2022-02-21

Start date

2022-04-18

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F00 G31 F06.7 F02

Interventions

Group 1: People with MCI or SCD will be called at six measurement time points at three-month intervals, either automatically or by a study staff member. Within the calls, there will be a recording of

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: CDR-value max. 0.5

Exclusion criteria

Exclusion criteria: Age 0.5, severe hearing loss

Design outcomes

Primary

Measure	Time frame
Validation of speech as biomarker in comparison with gold-standard biomarkers	—

Secondary

Measure	Time frame
Evaluation of users' acceptance regarding computer-based conduction of assessments measured by questionnaire and semi-structured interviews.	—

Countries

Germany, Spain, Sweden, United Kingdom

Contacts

Public ContactStefanie Köhler

Deutsches Zentrum für Neurodegenerative Erkrankungen

stefanie.koehler@dzne.de0381 494 9618

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026